Statement of Deviation & Variation for the Quarter ended June 30, 2026.

August 07, 2026 BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400001. Scrip Code: 531015 Sub: Statement of deviation or variation in the use of proceeds raised through Preferential Issue Dear Sir/Madam, Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that there is no deviation or variation in the use of proceeds raised through Preferential Issue from the objects stated in the EGM Notice for Preferential Issue. A statement confirming that there is no deviation or variation in the utilization of these proceeds for the quarter ended June 30, 2026, duly reviewed by the Audit Committee in the meeting held on 07.08.2026, is enclosed herewith as “Annexure A”. Kindly take the above information on record and oblige. Thanking You Yours Faithfully For Venmax Drugs & Pharmaceuticals Limited Venkata Rao Sadhanala Managing Director DIN: 02906370 Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009 CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM E-mail: venmaxdrugs@gmail.com Statement of Deviation / Variation in utilization of funds raised: Annexure A Name of listed entity Venmax Drugs and Pharmaceuticals Limited Mode of Fund Raising Issue of Fully Convertible Equity Warrants on Preferential Basis Date of Raising Funds March 20, 2025 Amount Raised Rs. 20.05 crores to be raised in total, out of which 1. Rs. 12.69 crores have been raised and received from investors against 63,44,000 conversions of share warrants. 2. 1.84 crores received against 36,81,000 share warrants. Report filed for Quarter ended June 30, 2026 Monitoring Agency NA Monitoring Agency Name, if applicable NA Is there a Deviation / Variation in use of No funds raised If yes, whether the same is pursuant to Not Applicable change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval February 6, 2025 Explanation for the Deviation /Variation Not Applicable Comments of the Audit Committee after NA review Comments of the auditors, if any Nil Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009 CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM E-mail: venmaxdrugs@gmail.com Objects for which funds have been raised: Original Object Modifie Original Revised Modifi Funds Amount of Remarks d Allocatio Allocation ed Utilise Deviation if any Object, n allocati d /Variation if any on, if for the any quarter according to applicable object 1. Working Capital Not Rs. 10 Not Not Till 30th Not No Applicabl crores Applicabl Applic June 2026, Applicable Deviation e e able Rs. 8.37 crores was utilized. 2. General Corporate Not Rs. 10.05 Not Not Till 30th Not No Purpose and Applicabl crores Applicabl Applic June 2026, Applicable Deviation Business e e able Rs. 0.20 Acquisition crores was utilized. For Venmax Drugs & Pharmaceuticals Limited Venkata Rao Sadhanala Managing Director DIN: 02906370 Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009 CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM E-mail: venmaxdrugs@gmail.com